The May 9 AP article in the FNP on the use of Pfizer’s Paxlovid noted that the current administration spent $10 billion to treat 20 million people. That’s $500 per person. But to treat with ivermectin would cost about $80 for 30 pills, and you would still have some left over.
The article mentioned that people still get COVID after its use, so there you have government spending (wasting) money to benefit the pharmaceutical industry (again) with little to no benefit to the patient. There are 82 studies that show the benefit of ivermectin (IVMMeta.com), but Merck (or Pfizer) won’t make much profit from its use since it’s now a generic.
A previous article by Michael Hiltzik (from the Los Angeles Times, April 4 in the FNP) about the Together Trial was a recent takedown attempt at ivermectin. But the author of that study even noted that if more patients were included, ivermectin would have been able to show benefit. And indeed it actually did show a benefit of reduction of length of stay even though the dosage of ivermectin was too low (See FLCCC.net, response to the study). That study was set up to fail. Paxlovid side effects are not mentioned in Tuesday's article. But its lack of efficacy is evident enough that patients are declining to take it.